Last updated: February 19, 2026
This analysis examines Chilean patent CL2013000033, focusing on its core patent claims, the therapeutic areas it covers, and the broader patent landscape relevant to its technological domain. The patent, titled "PROCEDIMIENTO PARA LA PRODUCCION DE VACUNAS DE ARN MENSAJERO VIRALES CON ENCAPSULACION EN LIPIDOS Y COMPOSICIONES," relates to the production of viral messenger RNA (mRNA) vaccines encapsulated in lipids.
What is the Scope of Patent CL2013000033?
The patent's scope is defined by its claims, which delineate the exclusive rights granted to the patent holder. CL2013000033 claims a method for producing viral mRNA vaccines and the resulting compositions. The method involves specific steps for producing and encapsulating mRNA. The compositions comprise the produced mRNA and lipid particles designed for effective delivery. The technology is centered on the manufacturing process of mRNA vaccines, specifically addressing the encapsulation of mRNA within lipid nanoparticles (LNPs).
The claims are structured to cover:
- A specific production method: This method likely details steps for synthesizing mRNA, purifying it, and formulating it into lipid-based delivery systems. The particularities of this method are crucial for determining infringement.
- The resulting vaccine compositions: These claims cover the final product of the claimed method, including the specific mRNA sequences and the lipid formulations used.
The patent's described technology is foundational for mRNA vaccine development, particularly concerning the stability and delivery mechanisms of mRNA. This is a critical aspect of vaccine formulation, as naked mRNA is susceptible to degradation and may not efficiently enter target cells. Lipid encapsulation is a well-established strategy for overcoming these challenges.
What are the Key Claims of CL2013000033?
The primary claims of CL2013000033 are directed towards a process for producing mRNA vaccines and the vaccine compositions themselves. Specific claim language, as detailed in the patent application, is essential for precise interpretation. However, based on the title and typical scope of such patents, the key claims are understood to encompass:
- Claim 1 (Independent Method Claim): This claim likely describes the core process for producing viral mRNA vaccines. It would specify the steps involved in generating viral mRNA, its purification, and its subsequent encapsulation into lipid particles. This might include details on the types of lipids used, the stoichiometry of components, and the encapsulation conditions (e.g., temperature, pH, mixing ratios).
- Dependent Method Claims: These claims would further refine or narrow down the process described in Claim 1. For instance, they might specify particular purification techniques, types of lipid components (e.g., ionizable lipids, phospholipids, cholesterol, PEG-lipids), or specific mRNA sequences or viral origins.
- Claim(s) for the Composition: These claims would cover the vaccine composition resulting from the claimed method. This includes the encapsulated mRNA and the lipid formulation. The claims would likely define the components of the lipid nanoparticles and their relative proportions, as well as the characteristics of the encapsulated mRNA (e.g., sequence, length, modification).
- Claims related to specific viral targets: Depending on the patent's breadth, claims may also cover the production of vaccines for specific viruses, such as influenza, SARS-CoV-2, or others.
The precise wording of these claims determines the boundaries of the patent protection. Infringement would occur if a competitor's process or product includes all the essential elements of a claimed invention. For example, a competitor's process for producing mRNA vaccines would infringe if it uses the specific steps outlined in Claim 1, or a combination of steps defined in dependent claims. Similarly, a competitor's vaccine product would infringe if it meets the structural and compositional requirements set forth in the composition claims.
Example of Claim Interpretation: If a claim specifies "an ionizable lipid with a pKa between 6.0 and 7.0," then any competitor using an ionizable lipid outside this pKa range might not infringe that specific claim. Conversely, using an ionizable lipid within this range, along with all other claimed elements, would constitute infringement.
The patent application for CL2013000033, accessible through the National Institute of Industrial Property of Chile (INAPI), would provide the definitive claim language.
What Therapeutic Areas Does CL2013000033 Cover?
The patent title explicitly states "PROCEDIMIENTO PARA LA PRODUCCION DE VACUNAS DE ARN MENSAJERO VIRALES." This indicates the primary therapeutic area is infectious diseases, specifically those preventable by vaccination.
The "virales" (viral) qualifier is key. The technology is designed to produce vaccines against viral pathogens. The specific viral targets are not necessarily limited to a single virus by the patent itself, but rather the underlying technology for producing viral mRNA vaccines. This broad applicability allows for the development of vaccines against a wide range of viral infections.
Potential therapeutic applications, depending on the specific mRNA sequences developed using this technology, include:
- Viral Respiratory Diseases: Vaccines against influenza, respiratory syncytial virus (RSV), and coronaviruses (including SARS-CoV-2).
- Viral Hepatitis: Vaccines against Hepatitis A, B, and C.
- Viral Hemorrhagic Fevers: Vaccines against Ebola, Marburg, and Dengue viruses.
- Other Viral Infections: Vaccines for rabies, poliomyelitis, measles, mumps, rubella, human papillomavirus (HPV), and emerging viral threats.
The patent's focus is on the platform technology for producing viral mRNA vaccines. This means that the same underlying manufacturing process and lipid encapsulation technology, described in CL2013000033, could theoretically be adapted to generate vaccines against various viral agents by simply changing the mRNA sequence encoding the viral antigen. This flexibility is a hallmark of mRNA vaccine platforms.
The broad scope in terms of viral targets is a significant aspect of its potential commercial value. It implies that the patent holder could license this foundational technology to multiple vaccine developers targeting different viral diseases, or develop vaccines for a portfolio of viral infections themselves.
What is the Patent Landscape for Viral mRNA Vaccines in Chile?
The patent landscape for viral mRNA vaccines is dynamic and increasingly crowded, particularly following the success of mRNA vaccines during the COVID-19 pandemic. In Chile, as in other jurisdictions, this landscape is shaped by both domestic innovation and the international filing strategies of major pharmaceutical and biotechnology companies.
Key players in the mRNA vaccine space globally include:
- Moderna, Inc.: A pioneer in mRNA technology, holding a substantial portfolio of patents related to mRNA therapeutics and vaccines.
- BioNTech SE (and Pfizer): Developed the first widely authorized mRNA COVID-19 vaccine, with extensive patent protection in this area.
- CureVac AG: Another early developer of mRNA technology, with its own distinct patent strategy.
The landscape in Chile can be analyzed by considering:
- Direct Competitors: Companies holding patents on similar mRNA production methods, lipid nanoparticle formulations, or specific viral mRNA vaccines. CL2013000033 directly addresses the production method and resulting compositions, placing it in direct competition with any entity developing or manufacturing mRNA vaccines using analogous technologies.
- Related Technologies: Patents covering mRNA synthesis, purification, delivery systems (beyond lipid nanoparticles, e.g., viral vectors, though less relevant for mRNA), and methods of use for vaccines.
- Freedom to Operate (FTO): Companies seeking to develop or market mRNA vaccines in Chile must conduct FTO analyses to ensure their products and processes do not infringe existing patents, including CL2013000033. This involves scrutinizing the claims of relevant patents.
- Patent Expiry: Understanding when existing patents expire is crucial for generic or biosimilar (for biologicals) market entry. However, for novel technologies like mRNA vaccines, many foundational patents are still in force.
- Chilean Patent Law: The specifics of Chilean patent law, including examination practices and patentability requirements, influence the granting and validity of patents.
Analysis of Patent Landscape Aspects:
-
Core mRNA Technology Patents: These patents cover fundamental aspects of mRNA technology, such as the use of specific chemical modifications to improve mRNA stability and immunogenicity, methods for producing specific types of mRNA (e.g., capped mRNA), and basic LNP formulations. CL2013000033 falls into this category by claiming a method for producing and encapsulating viral mRNA vaccines.
-
Specific Vaccine Product Patents: These patents cover particular vaccine candidates designed to target specific diseases. They often claim the mRNA sequence encoding a particular antigen, the specific LNP formulation used for that mRNA, and the use of the vaccine for treating or preventing a particular disease. CL2013000033, while focusing on the production method and composition, could be foundational for developing such specific product patents.
-
Manufacturing Process Patents: CL2013000033 is primarily a manufacturing process patent. This is a critical area of intellectual property, as it can provide a competitive advantage through efficiency, cost-effectiveness, or scalability. Other companies may hold patents on alternative or improved methods for mRNA synthesis, purification, or LNP encapsulation.
-
Composition of Matter Patents: Claims directed to the final vaccine composition (mRNA within lipid nanoparticles) are often considered the strongest type of patent, as they can cover the product regardless of how it was manufactured.
Potential Strategic Implications for CL2013000033:
- Licensing Opportunities: The holder of CL2013000033 may have opportunities to license this technology to other pharmaceutical companies looking to develop mRNA vaccines in Chile.
- Defensive Strategy: The patent can serve as a defensive asset, deterring competitors from using similar production methods.
- Litigation Risk: Companies operating in the mRNA vaccine space in Chile must be aware of this patent to avoid potential infringement litigation. A thorough FTO analysis is recommended.
- Prior Art: This patent might be cited as prior art against future patent applications in related fields, potentially limiting the scope of new inventions.
The patent landscape in Chile for viral mRNA vaccines is likely to include numerous applications and granted patents from global entities. The strength and enforceability of CL2013000033 will depend on factors such as its novelty, inventive step, and clarity of its claims when challenged against prior art and competing technologies.
The INAPI database is the primary source for detailed information on patent filings and grants within Chile. Analyzing INAPI data for keywords related to mRNA, lipid nanoparticles, viral vaccines, and specific viral targets would provide a comprehensive overview of the competitive patent landscape.
Table 1: Key Players in mRNA Vaccine Technology (Global Context)
| Company |
Primary Focus |
Notable Technologies/Products |
| Moderna, Inc. |
mRNA therapeutics and vaccines |
mRNA-1273 (COVID-19 vaccine), mRNA platform |
| BioNTech SE |
mRNA-based therapies |
BNT162b2 (COVID-19 vaccine with Pfizer), cancer immunotherapies |
| CureVac AG |
mRNA-based vaccines and therapeutics |
CVnCoV (COVID-19 vaccine candidate), oncology programs |
Note: This table represents key global players and does not specifically detail their Chilean patent portfolios, which require specific database searches.
Key Takeaways
- Patent CL2013000033 claims a method for producing viral mRNA vaccines and the resulting lipid-encapsulated compositions.
- The therapeutic scope is broad, covering vaccines against various viral infectious diseases due to its focus on a foundational production platform.
- The patent landscape for viral mRNA vaccines in Chile is competitive, influenced by global innovators and requiring careful Freedom to Operate analysis for any new market entrants.
Frequently Asked Questions
-
What specific types of lipids are covered by the patent claims?
The precise types of lipids are defined by the claim language within the patent document. Typically, such patents cover ionizable lipids, phospholipids, cholesterol, and PEG-lipids, but specific formulations and ratios are critical.
-
Does this patent prevent the use of any mRNA vaccine, or only those produced by a specific method?
The patent primarily claims a specific method of production and the resulting composition. While it can influence market entry for those using the claimed method or composition, it does not inherently prevent all mRNA vaccines if they are produced using fundamentally different technologies or result in different compositions.
-
How long is patent CL2013000033 expected to be in force in Chile?
In Chile, utility patents generally have a term of 20 years from the filing date, subject to payment of annual fees. The filing date of CL2013000033 would determine its expiry.
-
Can this patent be licensed to other companies for vaccine development?
Yes, patent holders can grant licenses to third parties, allowing them to use the patented technology under agreed-upon terms, which is a common strategy in the pharmaceutical industry.
-
What is the process for challenging the validity of patent CL2013000033 in Chile?
Patent validity can be challenged through legal proceedings, typically involving demonstrating that the invention lacked novelty, an inventive step, or sufficient disclosure at the time of filing, or that it does not meet other patentability criteria. Such challenges are usually initiated at the relevant Chilean courts or through administrative procedures at INAPI.
Citations
[1] National Institute of Industrial Property of Chile (INAPI). (n.d.). Patent Database. Retrieved from www.inapi.cl (Specific patent number CL2013000033 would be searched within this database).
